×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of ...
Yahoo Finance
CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company...
5 months ago
Qualigen Therapeutics Ends Deal with Pan-RAS Holdings - TipRanks.com
Tipranks
The latest update is out from Qualigen Therapeutics Inc (QLGN). A Termination Agreement was finalized on March 25, 2024, ending a prior...
1 month ago
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
BioSpace
Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in...
7 months ago
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research ...
Yahoo Finance
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen...
3 weeks ago
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
GlobeNewswire
Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack®...
8 months ago
Qualigen Therapeutics Secures Investment and Expands Financing Options - TipRanks.com
Tipranks
Qualigen Therapeutics Inc (QLGN) has issued an announcement. Qualigen Therapeutics, Inc. has struck a deal with Alpha Capital Anstalt,...
2 months ago
FDA clears Qualigen's IND for trial of solid tumour therapy
Clinical Trials Arena
The FDA has granted clearance to Qualigen Therapeutics' IND for initiating a Phase I trial of QN-302 to treat metastatic solid tumours.
9 months ago
Chembio buys Qualigen's FastPack diagnostics business
Medical Device Network
Chembio Diagnostics has acquired the FastPack diagnostics business from Qualigen Therapeutics in an all-cash transaction.
9 months ago
Qualigen Therapeutics to advance QN-302 into clinical studies
BioWorld MedTech
The FDA has cleared Qualigen Therapeutics Inc.'s IND application for QN-302, a potential best-in-class small molecule G-Quadruplex...
9 months ago
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in ...
Yahoo Finance
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces...
3 weeks ago